IPHARMA took a part in XXIV Russian National Congress "Human and drug"
On April, 12 IPHARMA took a part in XXIV Russian National Congress “Human and drug”.
The congress is the partner of Pharma 2020 Programm and aimed to scientific experience and knowledges exchange.
Authentic information expansion is the main object of the Congress. There is courses and scientific symposiums for participants, doctors and research officers.
Natalia Vostokova, IPHARMA Chief Operating Officer presented the report “Comparison of the novel Russian DPP-4 inhibitor gosogliptin with vildagliptin in patients with type 2 diabetes mellitus” under the Skolkovo session of Congress.
Gozogliptin (SatRx®) was developed by SatRx (ChemRar) and was registered in June 2016. A full production cycle was conducted on the territory of the Russian Federation.
The listeners was interested in the report. They put a questions about results of clinical trial and safety of the drug.